Trial Profile
A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs THR 317 (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Sponsors Oxurion
- 01 Sep 2020 Status changed from recruiting to completed.
- 19 Dec 2019 According to an Oxurion media release, results from this study are expected to be presented at a scientific conference in 2020.
- 18 Oct 2019 According to an Oxurion media release, topline data from this study is expected in early 2020.